Cost-effectiveness and pricing of antibacterial drugs

Chemical Biology and Drug Design

Volumn 85, Issue 1, 2015, Pages 4-13

  Verhoef, Talitha I ^a   Morris, Stephen ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antibacterial drugs; antibiotics; cost effectiveness; health economics; value based pricing

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; ECONOMIC EVALUATION; HEALTH INSURANCE; HUMAN; LIFE EXPECTANCY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; VISUAL ANALOG SCALE; COST; COST BENEFIT ANALYSIS; DRUG DESIGN; ECONOMICS;

BACTERIA (MICROORGANISMS);

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG DESIGN;

EID: 84918809267     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12417     Document Type: Article

References (62)

1. Zaffiri L., Gardner J., Toledo-Pereyra L.H., (2012) History of antibiotics. From salvarsan to cephalosporins. J Invest Surg; 25: 67-77.
2. Butler M.S., Blaskovich M.A., Cooper M.A., (2013) Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo); 66: 571-591.
3. Norrby S.R., Nord C.E., Finch R., (2005) Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis; 5: 115-119.
4. Outterson K., Samora J.B., Keller-Cuda K., (2007) Will longer antimicrobial patents improve global public health? Lancet Infect Dis; 7: 559-566.
5. Projan S.J., (2003) Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol; 6: 427-430.
6. Torrance G.W., (1986) Measurement of health state utilities for economic appraisal. J Health Econ; 5: 1-30.
7. EuroQol Group. (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy; 16: 199-208.
8. Shiroiwa T., Sung Y.K., Fukuda T., Lang H.C., Bae S.C., Tsutani K., (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ; 19: 422-437.
9. Redondo E., Nocea G., (2003) Cost-effectiveness analysis of ertapenem (Invanz) in intra-abdominal infections compared to piperacillin/tazobactam. Revista Espanola de Economia de la Salud; 2: 306-310.
10. Rubio-Terres C., Cots J.M., Dominguez-Gil A., Herreras A., Sanchez G.F., Chang J., Trilla A., (2003) Pharmacoeconomic analysis of community-acquired pneumonia treatment with telithromycin or clarithromycin. Rev Esp Quimioter; 16: 295-303.
11. Rubio-Terres C., Cots J.M., Dominguez-Gil A., Herreras A., Sanchez Gascon F., Chang J., Trilla A., (2004) Pharmacoeconomic analysis of patients with acute exacerbation of chronic bronchitis treated with telithromycin or cefuroxime-axetil. Rev Clin Esp; 204: 567-573.
12. Phillips S., MacDougall C., Holdford D.A., (2007) Analysis of empiric antimicrobial strategies for cellulitis in the era of methicillin-resistant Staphylococcus aureus. Ann Pharmacother; 41: 13-20.
13. Brown K.R., Williams S.F., Apuzzio J.J., (2012) Ertapenem compared to combination drug therapy for the treatment of postpartum endometritis after cesarean delivery. J Matern Fetal Neonatal Med; 25: 743-746.
14. Gonzalez-Ruiz A., Richardson J., (2008) Are glycopeptides still appropriate and convenient for empiric use? J Chemother; 20: 531-541.
15. Hermsen E.D., Shull S.S., Mitropoulos I.F., Puumala S.E., Rupp M.E., (2009) Prospective evaluation of clinical and economic outcomes associated with treatment of serious infections due to gram-positive cocci. Infect Dis Clin Pract; 17: 17-21.
16. Kullar R., Davis S.L., Kaye K.S., Levine D.P., Pogue J.M., Rybak M.J., (2013) Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia. Pharmacotherapy; 33: 3-10.
17. McKinnon P.S., Carter C.T., Girase P.G., Liu L.Z., Carmeli Y., (2007) The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Manag Care Interface; 20: 23-34.
18. Merchant S., Gast C., Nathwani D., Lee M., Quintana A., Ketter N., Friedland I., Ingham M., (2008) Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther; 30: 717-733.
19. Sclar D.A., Robison L.M., Oganov A.M., Schmidt J.M., Bowen K.A., Castillo L.V., (2012) Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price. Clin Drug Investig; 32: e17-e24.
20. Wright B.M., Eiland E.H. 3rd, (2011) Retrospective analysis of clinical and cost outcomes associated with methicillin-resistant Staphylococcus aureus complicated skin and skin structure infections treated with daptomycin, vancomycin, or linezolid. J Pathog; 2011: 347969.
21. Bhavnani S.M., Ambrose P.G., (2008) Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn Microbiol Infect Dis; 60: 59-64.
22. Bhavnani S.M., Prakhya A., Hammel J.P., Ambrose P.G., (2009) Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis. Clin Infect Dis; 49: 691-698.
23. Bounthavong M., Hsu D.I., Okamoto M.P., (2009) Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Int J Clin Pract; 63: 376-386.
24. Bounthavong M., Zargarzadeh A., Hsu D.I., Vanness D.J., (2011) Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health; 14: 631-639.
25. Campbell M.L., Marchaim D., Pogue J.M., Sunkara B., Bheemreddy S., Bathina P., Pulluru H., et al,. (2012) Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 mug/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmacother; 46: 1587-1597.
26. Davis S.L., McKinnon P.S., Hall L.M., Delgado G. Jr, Rose W., Wilson R.F., Rybak M.J., (2007) Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy; 27: 1611-1618.
27. De Cock E., Krueger W.A., Sorensen S., Baker T., Hardewig J., Duttagupta S., Muller E., Piecyk A., Reisinger E., Resch A., (2009) Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infection; 37: 123-132.
28. De Cock E., Sorensen S., Levrat F., Besnier J.M., Dupon M., Guery B., Duttagupta S., (2009) Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France. Med Mal Infect; 39: 330-340.
29. Grau S., Aguado J.M., Mateu-de Antonio J., Gonzalez P., Del Castillo A., (2007) Economic evaluation of linezolid versus teicoplanin for the treatment of infections caused by gram-positive microorganisms in Spain. J Chemother; 19: 398-409.
30. Grau S., Mateu-de Antonio J., Soto J., Marin-Casino M., Salas E., (2005) Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms. Pharm World Sci; 27: 459-464.
31. Halpern M.T., Palmer C.S., Zodet M., Kirsch J., (2002) Cost-effectiveness of gemifloxacin: results from the GLOBE study. Am J Health Syst Pharm; 59: 1357-1365.
32. Jansen J.P., Kumar R., Carmeli Y., (2009) Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. Value Health; 12: 234-244.
33. Jansen J.P., Kumar R., Carmeli Y., (2009) Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. PharmacoEconomics; 27: 1045-1056.
34. Kongnakorn T., Mwamburi M., Merchant S., Akhras K., Caro J.J., Nathwani D., (2010) Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. Curr Med Res Opin; 26: 17-24.
35. Laohavaleeson S., Barriere S.L., Nicolau D.P., Kuti J.L., (2008) Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy; 28: 1471-1482.
36. Machado A.R., Arns Cda C., Follador W., Guerra A., (2005) Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Braz J Infect Dis; 9: 191-200.
37. Mullins C.D., Kuznik A., Shaya F.T., Obeidat N.A., Levine A.R., Liu L.Z., Wong W., (2006) Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther; 28: 1184-1198.
38. Niederman M.S., Chang J.R., Stewart J., Asche C.V., Lavin B., Nusrat R., Sullivan S.D., (2004) Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials. Curr Med Res Opin; 20: 969-980.
39. Niederman M.S., Chang J.R., Stewart J., Nusrat R., Nieman R.B., (2004) Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin. Curr Med Res Opin; 20: 749-756.
40. Patanwala A.E., Erstad B.L., Nix D.E., (2007) Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Curr Med Res Opin; 23: 185-193.
41. Sabes-Figuera R., Segu J.L., Puig-Junoy J., Torres A., (2008) Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia. Eur J Health Econ; 9: 23-32.
42. Schurmann D., Sorensen S.V., De Cock E., Duttagupta S., Resch A., (2009) Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Eur J Health Econ; 10: 65-79.
43. Shorr A.F., Susla G.M., Kollef M.H., (2004) Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med; 32: 137-143.
44. Stein G.E., Schooley S.L., Havlichek D.H., Nix D.E., (2008) Outpatient intravenous antibiotic therapy compared with oral linezolid in patients with skin and soft tissue infections: a pharmacoeconomic analysis. Infect Dis Clin Pract; 16: 235-239.
45. Stranges P.M., Hutton D.W., Collins C.D., (2013) Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health; 16: 297-304.
46. Tellier G., Chang J.R., Asche C.V., Lavin B., Stewart J., Sullivan S.D., (2004) Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Curr Med Res Opin; 20: 739-747.
47. Vinken A.G., Li J.Z., Balan D.A., Rittenhouse B.E., Willke R.J., Goodman C., (2003) Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals. Am J Ther; 10: 264-274.
48. Zilberberg M.D., Mody S.H., Chen J., Shorr A.F., (2010) Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia. Surg Infect (Larchmt); 11: 409-417.
49. Grau S., Alvarez-Lerma F., del Castillo A., Neipp R., Rubio-Terres C., (2005) Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain. J Chemother; 17: 203-211.
50. Grau S., Lozano V., Valladares A., Cavanillas R., Xie Y., Nocea G., (2014) Antibiotic expected effectiveness and cost under real life microbiology: evaluation of ertapenem and ceftriaxone in the treatment of community-acquired pneumonia for elderly patients in Spain. Clinicoecon Outcomes Res; 6: 83-92.
51. Konijeti G.G., Sauk J., Shrime M.G., Gupta M., Ananthakrishnan A.N., (2014) Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis; 58: 1507-1514.
52. McComb M.N., Collins C.D., (2014) Comparative cost-effectiveness of alternative empiric antimicrobial treatment options for suspected enterococcal bacteremia. Pharmacotherapy; 34: 537-544.
53. McGarry L.J., Merchant S., Nathwani D., Pawar V., DeLong K., Thompson D., Akhras K., Ingham M., Weinstein M.C., (2010) Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Journal of medical economics; 13: 142-147.
54. Tan S.C., Wang X., Wu B., Kang H., Li Q., Chen Y., Chen C.I., Hajek P., Patel D.A., Gao X., (2014) Cost-effectiveness of linezolid versus vancomycin among patients with methicillin-resistant staphylococcus aureus confirmed nosocomial pneumonia in China. ViHRI; 3: 94-100.
55. Vinken A., Li Z., Balan D., Rittenhouse B., Wilike R., Nathwani D., (2001) Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model. J Hosp Infect; 49 (Suppl A): S13-S24.
56. Wagner M., Lavoie L., Goetghebeur M., (2014) Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada. Can J Infect Dis Med Microbiol; 25: 87-94.
57. Wilson S.E., Turpin R.S., Kumar R.N., Itani K.M., Jensen E.H., Pellissier J.M., Abramson M.A., (2008) Comparative costs of ertapenem and cefotetan as prophylaxis for elective colorectal surgery. Surg Infect (Larchmt); 9: 349-356.
58. Bartsch S.M., Umscheid C.A., Fishman N., Lee B.Y., (2013) Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis; 57: 555-561.
59. Raftery J., (2013) Value based pricing: can it work? BMJ; 347: f5941.
60. Claxton K., Briggs A., Buxton M.J., Culyer A.J., McCabe C., Walker S., Sculpher M.J., (2008) Value based pricing for NHS drugs: an opportunity not to be missed? BMJ; 336: 251-254.
61. Marsh K., Lanitis T., Neasham D., Orfanos P., Caro J., (2014) Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature. PharmacoEconomics; 32: 345-365.
62. Sussex J., Towse A., Devlin N., (2013) Operationalizing value-based pricing of medicines: a taxonomy of approaches. PharmacoEconomics; 31: 1-10.